Discovery of potent, selective and orally bioavailable imidazo[1,5-a] pyrazine derived ACK1 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 4, 2013, Pages 979-984

  Jin, Meizhong ^a   Wang, Jing ^a   Kleinberg, Andrew ^a   Kadalbajoo, Mridula ^a   Siu, Kam W ^a   Cooke, Andrew ^a   Bittner, Mark A ^a   Yao, Yan ^a   Thelemann, April ^a   Ji, Qunsheng ^a   Bhagwat, Shripad ^a   Mulvihill, Kristen M ^a   Rechka, Josef A ^a   Pachter, Jonathan A ^a   Crew, Andrew P ^a   Epstein, David ^a   Mulvihill, Mark J ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

Activated Cdc42 associated kinase (ACK1); Cancer; Imidazo 1,5 a pyrazine; Inhibitors; Structure activity relationships (SAR)

Indexed keywords

ACTIVATED CDC42 ASSOCIATED KINASE; IMIDAZO[1,5 A]PYRAZINE DERIVATIVE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; IC 50; MOUSE; NONHUMAN; QUANTUM CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; IMIDAZOLES; MICE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872981225     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.12.042     Document Type: Article

References (22)

1. E. Manser, T. Leung, H. Salihuddin, L. Tan, and L. Lim Nature 27 1993 364
2. Prieto-Echague, V.; Miller, W. T. J. Signal Transduct. 2011, article ID 742372.
3. K. Mahajan, and N.P. Mahajan J. Cell. Physiol. 224 2010 327
4. B.T. Chua, S.J. Lim, S.C. Tham, W.J. Poh, and A. Ullrich Mol. Oncol. 4 2010 323
5. E.H. Van der Horst, Y.Y. Degenhardt, A. Strelow, A. Slavin, L. Chinn, J. Orf, M. Rong, S. Li, L.H. See, K.Q. Nguyen, T. Hoey, H. Wesche, and S. Powers Proc. Natl. Acad. Sci. U.S.A. 102 2005 15901
6. N.P. Mahajan, Y.E. Whang, J.L. Mohler, and H.E. Earp Cancer Res. 65 2005 10514
7. N.P. Mahajan, Y. Liu, S. Majumder, M.R. Warren, C.E. Parker, J.L. Mohler, H.S. Earp, and Y.E. Whang Proc. Natl. Acad. Sci. U.S.A. 104 2007 8438
8. K. Mahajan, D. Coppola, S. Challa, B. Fang, Y.A. Chen, W. Zhu, A.S. Lopez, J. Koomen, R.W. Engelman, C. Rivera, R.S. Muraoka-Cook, J.Q. Cheng, E. Schönbrunn, S.M. Sebti, H.S. Earp, and N.P. Mahajan PLoS One 5 2010 e9646
9. D. Kopecky, X. Hao, Y. Chen, J. Fu, X. Jiao, J. Jaen, M. Cardozo, J. Liu, Z. Wang, N. Walker, H. Wesche, S. Li, E. Farrelly, S. Xiao, and F. Kayser Bioorg. Med. Chem. Lett. 18 2008 6352
10. Kopecky, D.; Burkitt, S.; Clase, A.; Farelli, E.; Farthing, C.; Faulder, P.; Frenkel, D.; Harrison, M.; Jaen, J.; Jiao, X.; Kayser, F.; Li, S.; Liu, J.; Liu, J.; Lively, S.; Sharma, R.; Strelow, A.; Van der Horst, E.; Wang, Z.; Wesche, H.; Xiao, S. Abstracts of Papers, 232nd National Meeting of the American Chemical Society, San Fransisco, CA; American Chemical Society: Washington, DC, 2006, MEDI 106.
11. Liu, J.; Sharma, R.; Lively, S.; Burkitt, S.; Clase, A.; Farthing, C.; Jiao, X. Y.; Kopecky, D.; Kayser, F.; Shuttelworth, S.; Harrison, M.; Faulder, P.; Li, S.; Wesche, H.; Mallari, R.; Farrelly, E.; Xiao, S. -H.; Liu, J.; Wang, Z.; Jaen, J. Abstracts of Papers, 232nd National Meeting of the American Chemical Society, San Fransisco, CA; American Chemical Society: Washington, DC, 2006, MEDI 105.
12. Lively, S.; Burkitt, S.; Cardozo, M.; Clase, A.; Farelli, E.; Farthing, C.; Faulder, P.; Harrison, M.; Jaen, J.; Jiao, X.; Kayser, F.; Kopecky, D.; Li, S.; Liu, J.; Liu, J.; Mallari, R.; Sharma, R.; Strelow, A.; Van der Horst, E.; Wang, Z.; Wesche, H.; Xiao, S. Abstracts of Papers, 232nd National Meeting of the American Chemical Society, San Fransisco, CA; American Chemical Society: Washington, DC, 2006, MEDI 107.
13. X. Jiao, D.J. Kopecky, J. Liu, J. Liu, J.C. Jaen, M.G. Cardozo, R. Sharma, N. Walker, H. Wesche, S. Li, E. Farrelly, S.H. Xiao, Z. Wang, and F. Kayser Bioorg. Med. Chem. Lett. 22 2012 6212
14. K. Mahajan, S. Challa, D. Coppola, H. Lawrence, Y. Luo, H. Gevariya, W. Zhu, Y. Chen, N. Lawrence, and N.P. Mahajan Prostate 70 2010 1274
15. Crew, A. P.; Jin, M.; Kadalbajoo, M.; Kleinberg, A.; Mulvihill, M. J.; Wang, J. US 20090286768. Detailed biochemical assay and cellular mechanistic assay protocols, as well as synthesis of key intermediates and final compounds are described therein.
16. C. Laurence, K.A. Brameld, J. Graton, J.Y. Le Questel, and E. Renault J. Med. Chem. 52 2009 4073
17. The calculations were performed with Jaguar program version 6.5 licensed from Schrodinger, Inc., Poland, OR. The B3LYP functional and 6-31G basis set were used. To obtain the free state conformation of a compound, the geometrical optimizations with multiple starting points were performed.
18. C. Bissantz, B. Kuhn, and M. Stahl J. Med. Chem. 53 2010 5061
19. 2 = 0.76).
20. Compound 42 showed >80% inhibition to following kinases (other than ACK1) when screened at 1.0 μM against 216 kinases: BLK, FGR, FRK, FYN, HCK, LCK, LYNB, SRC, SRMS, TEC, TXK, YES.
21. Selectivity score is a quantitative measure of compound selectivity. It is calculated as such: selectivity score = (number of hits)/(number of assays). S(10) is calculated using 10% control as a potency threshold: S(10) = (number of kinases with % control <10)/(number of kinases tested). Further information regarding to selectivity score is available at http://www.kinomescan.com.
22. D.A. Evans, J.L. Katz, and T.R. West Tetrahedron Lett. 39 1998 2937